Rebion, Inc.

Rebion, Inc. commercializes Neural Performance Scanning (NPS), a proprietary technology platform that measures neurophysiologic mechanisms of the optic nerve/brain continuum through retinal scanning. The company's primary product, Blinq®, is an FDA-cleared portable point-of-care neural performance scanner designed for pediatric vision screening. Blinq directly detects micro-strabismus and amblyopia (lazy eye) by quantifying bilateral fixation and saccadic eye movements, achieving up to 100% sensitivity and over 90% specificity in clinical evaluations. The device performs a 3-second neural performance scan capable of detecting binocularity impairments associated with as little as 1-degree misalignment. Rebion's technology is supported by peer-reviewed clinical studies and research conducted at major medical institutions. The company also develops Traq™, an investigational device leveraging NPS to measure visual tracking impairments for clinical research purposes (currently not available for sale in the United States). Rebion serves diverse markets including community screeners, schools and administrators, clinical staff, parents, and caregivers. The platform enables early disease detection, intervention, and customized treatment across clinics, schools, and public health initiatives, reducing unnecessary referrals while improving diagnostic accuracy and patient outcomes.